<DOC>
	<DOCNO>NCT00742560</DOCNO>
	<brief_summary>A Phase 1b/2 , Multicenter , Open-label , Dose-escalation Study Elotuzumab ( Humanized Anti CS1 Monoclonal IgG1 Antibody ) Combination Lenalidomide Dexamethasone Subjects Relapsed Multiple Myeloma .</brief_summary>
	<brief_title>A Phase 1b/2 , Dose-Escalation Study Elotuzumab ( Humanized Anti-CS1 Monoclonal IgG1 Antibody ) Relapsed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>1 . Age 18 year old confirm diagnosis MM documentation one three prior therapy . 2 . Confirmed evidence disease progression immediately prior MM therapy refractory immediately prior treatment . 3 . Measurable disease M protein component serum ( least 0.5 g/dL ) and/or urine ( present ) , ( &gt; =0.2 g excrete 24 hour collection sample ) . Subjects free light chain disease exclude . 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 . 5 . Creatinine clearance &gt; =50 mL/min measure CockcroftGault method . 6 . Hematologic parameter define : Absolute neutrophil count &gt; 1000 cells/mm^3 without growth factor 7 day . Platelets &gt; =75,000 cells/mm^3 ( 75 × 10^9/L ) , without platelet transfusion , within 72 hour screen evaluation . Hemoglobin &gt; =8 g/dL without red blood cell transfusion within 72 hour screen . 7 . Alanine aminotransferase ( ALT ) AND aspartate aminotransferase ( AST ) &lt; 3 × upper limit normal . 8 . Total bilirubin &lt; 2 × upper limit normal , direct bilirubin &lt; 2.0 mg/dL . 9 . Negative urine pregnancy test woman childbearing potential screening prior prescribe lenalidomide . Females childbearing potential ( FCBP ) must either commit continued abstinence heterosexual intercourse begin acceptable method birth control 28 day prior prescribe lenalidomide . Men must agree use latex condom sexual contact FCBP even successful vasectomy , must agree donate semen study drug therapy period time therapy . 10 . Able understand purpose risk study provide sign date informed consent authorization use protect health information ( accordance national local subject 's privacy regulation ) . 11 . Able take aspirin daily prophylactic anticoagulation therapy ( subject intolerant aspirin may use warfarin lowmolecularweight heparin ) . 1 . Prior malignancy , except adequately treat basal cell squamous cell skin cancer , insitu cervical cancer , cancer subject diseasefree least 2 year . 2 . Active prior plasma cell leukemia ( define either 20 % peripheral WBC comprise plasma/CD138+ cell absolute count 2 x 10^9/L ) . 3 . Uncontrolled medical problem diabetes mellitus , coronary artery disease , hypertension , unstable angina , arrhythmia , pulmonary disease , symptomatic heart failure . 4 . Solitary bone solitary extramedullary plasmacytoma evidence plasma cell dyscrasia . 5 . Treatment investigational drug within 2 week 3 half life ( whichever longer ) first dose elotuzumab . 6 . Use corticosteroid , thalidomide , bortezomib , cytotoxic chemotherapy within 2 week first dose elotuzumab except steroid little systemic absorption ( ie , topical inhale steroid ) . 7 . Prior lenalidomide therapy . 8 . Prior peripheral stemcell transplant within 12 week first dose elotuzumab . 9 . Treatment nitrosoureas , carmustine ( BiCNU ) , nitrogen mustard agent , melphalan , within 6 week first dose elotuzumab . 10 . Neuropathy &gt; =Grade 3 painful neuropathy &gt; =Grade 2 ( National Cancer Institute Common Terminology Criteria Adverse Events [ NCI CTCAE ] v3.0 ) . 11 . Known active infection require IV antibiotic , antiviral , antifungal therapy . 12 . Hypersensitivity recombinant proteins excipients elotuzumab , lenalidomide , dexamethasone . 13 . Female subject pregnant breastfeeding . 14 . Subjects serum calcium ( correct albumin ) &gt; = 12 mg/dL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
</DOC>